Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKN1 | Q16512 | 1/20 | 0.59 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.59 |
| ▸ | RHEB | Q15382 | 1/20 | 0.59 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.55 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6062255 | 0.86 | RHEB (0.54) | PKN1PKN2RHEBCHEK2DGAT1 | |
| SCHEMBL1842081 | 0.85 | RHEB (0.59) | PKN1PKN2RHEBCHEK2DGAT1 | |
| SCHEMBL3333407 | 0.85 | RHEB (0.68) | PKN1PKN2RHEBCHEK2DGAT1 | |
| SCHEMBL8412123 | 0.85 | RHEB (0.59) | PKN1PKN2RHEBCHEK2DGAT1 | |
| SCHEMBL19994470 | 0.85 | RHEB (0.59) | PKN1PKN2RHEBCHEK2DGAT1 | |
| SCHEMBL28267390 | 0.85 | CHEK2 (0.61) | PKN1PKN2RHEBCHEK2DGAT1 | |
| SCHEMBL30343743 | 0.85 | RHEB (0.56) | PKN1PKN2RHEBCHEK2DGAT1 | |
| SCHEMBL31027982 | 0.85 | HDAC6 (0.59) | PKN1PKN2RHEBCHEK2DGAT1 | |
| SCHEMBL21705379 | 0.85 | HDAC6 (0.59) | PKN1PKN2RHEBCHEK2DGAT1 | |
| SCHEMBL10765155 | 0.85 | RHEB (0.59) | PKN1PKN2RHEBCHEK2DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116635028-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-11-24 | — | — | US | disclosed |
| WO-2022150316-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| US-8168665-B2 | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-01 | — | — | US | disclosed |
| US-8168665-B2 | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-01 | — | — | US | disclosed |
| US-8168665-B2 | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-01 | — | — | US | disclosed |
| EP-2079709-B1 | SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2011-05-18 | — | — | EP | disclosed |
| EP-2079709-B1 | SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2011-05-18 | — | — | EP | disclosed |
| US-20090239915-A1 | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2009-09-24 | — | — | US | disclosed |
| US-20090239915-A1 | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2009-09-24 | — | — | US | disclosed |
| US-20090239915-A1 | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2009-09-24 | — | — | US | disclosed |
| EP-2079709-A1 | SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008037381-A1 | SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008037381-A1 | SUBSTITUTED 2-PHENYL-BENZIMIDAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-04-03 | — | — | WO | disclosed |
| EP-1905764-A1 | Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals | Sanofi-Aventis (FR) | 2008-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370431-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | PKN1 1949/4885PKN2 2272/4885RHEB 211/4885 |
| US-20090239915-A1 | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals | NOS2, NOS3, NOS1 | PKN1 242/4885PKN2 186/4885RHEB 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.